Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) EBITDA (2016 - 2025)

Heron Therapeutics' EBITDA history spans 14 years, with the latest figure at -$2.9 million for Q4 2025.

  • For Q4 2025, EBITDA fell 181.13% year-over-year to -$2.9 million; the TTM value through Dec 2025 reached -$20.2 million, down 48.78%, while the annual FY2025 figure was -$20.2 million, 48.78% down from the prior year.
  • EBITDA reached -$2.9 million in Q4 2025 per HRTX's latest filing, up from -$17.5 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $3.6 million in Q4 2024 to a low of -$63.9 million in Q1 2022.
  • Average EBITDA over 5 years is -$27.4 million, with a median of -$22.4 million recorded in 2022.
  • The largest YoY upside for EBITDA was 182.51% in 2025 against a maximum downside of 264.46% in 2025.
  • A 5-year view of EBITDA shows it stood at -$54.6 million in 2021, then soared by 63.71% to -$19.8 million in 2022, then soared by 45.99% to -$10.7 million in 2023, then soared by 133.95% to $3.6 million in 2024, then crashed by 181.13% to -$2.9 million in 2025.
  • Per Business Quant, the three most recent readings for HRTX's EBITDA are -$2.9 million (Q4 2025), -$17.5 million (Q3 2025), and -$2.4 million (Q2 2025).